GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US clinical stage caner drug developer Theriva Biologics revealed that the US Food and Drug Administration (FDA) has granted Rare Pediatric Drug designation (RPDD) for VCN-01 for the treatment of retinoblastoma. 1 August 2024
Eisai and Biogen have announced that Israel has approved their Alzheimer's treatment, Leqembi (lecanemab), adding to nods in the USA, Japan, China, South Korea, and Hong Kong. 12 July 2024
Contract research and development organization (CDMO) Emergent BioSolutions has announced that Johnson & Johnson will pay $50 million to resolve claims linked to a terminated manufacturing deal for the latter’s COVID-19 vaccine. 11 July 2024
Japan’s Eisai and US biotech Biogen have announced that the Department of Health in Hong Kong has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for treatment of Alzheimer’s disease (AD). 11 July 2024
PolTREG, a Polish biotech developing cell therapies for autoimmune diseases, has announced that its polyclonal Treg cell therapy PTG-007 demonstrated significant insulin secretion restoration in early-onset type-1 diabetes (T1D) patients, as well as a longer period of disease remission compared to a control group receiving standard-of-care. 24 June 2024
Indian drugmaker Cipla announced that its wholly-owned subsidiary in the UK, Cipla (EU) Limited, will invest an additional 3 million euros ($3.2 million) in Ethris GmbH, a German firm delivering mRNAs directly to the respiratory system. 19 June 2024
Dutch autoimmune diseases specialist Argenx announced that results from the Phase II ALPHA study of efgartigimod in post-COVID-19-mediated postural orthostatic tachycardia syndrome (PC-POTS) show that treated patients had no clinically meaningful improvement compared to placebo on the total Malmö POTS symptom (MaPS) score and COMPASS31. 17 June 2024
The US Food and Drug Administration (FDA) has accepted Eisai’s supplemental Biologics License Application (sBLA) for monthly Leqembi (lecanemab-irmb) intravenous (IV) maintenance dosing. 10 June 2024
The European Medicines Agency (EMA) has approved a Type II variation to the Summary of Product Characteristics (SmPC) for its approved Chimeric Antigen Receptor (CAR) T-cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) from Gilead Sciences’ Kite subsidiary. 6 June 2024
China, Canada and the USA are all represented in a collaboration to jointly develop a therapy for neurologic disorders by harnessing the natural power of the immune system. 8 April 2019
Shares in oncology specialist Merrimack Pharmaceuticals closed 16% down on Friday after the US company announced that it was discontinuing development of MM-310, its antibody-directed nanotherapeutic for the treatment of solid tumors. 8 April 2019
The research phase of the RNAi therapeutics collaboration between Sanofi and Alnylam Pharmaceuticals is over, the companies have announced. 8 April 2019
Japanese pharma major Eisai says that its in-house discovered fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor E7090 has been granted the Sakigake designation by Japan’s Ministry of Health, Labor and Welfare for the treatment of unresectable biliary tract cancer with FGFR2 gene fusion. 8 April 2019
Chinese biotechs will seek more cross-border licensing deals in the coming years, especially for early-stage assets, said speakers at the annual China Healthcare Investment Conference (CHIC) held in late March in Shanghai. 8 April 2019
US biotech major Celgene and Acceleron Pharma today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, 8 April 2019
The European Medicines Agency has granted a PRIME (PRIority MEdicines) designation for the investigational B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, JNJ-68284528 (JNJ-4528). 5 April 2019
Bristol-Myers Squibb has secured a positive reimbursement decision for its Opdivo (nivolumab) plus Yervoy (ipilimumab) combination, for use against kidney cancer, in the UK. 5 April 2019
Switzerland-based Roivant Sciences today announced the launch of Cytovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative cellular therapeutics in Asia, together with its previously spun-out “vant” company Sinovant Sciences. 4 April 2019
Investors in USA-based AVEO Oncology appear to be fearing the worst after the future of the company’s lead candidate was thrown into doubt. 4 April 2019
Biogen and Novartis have been given a reminder of their responsibility to patients in pricing their spinal muscular atrophy (SMA) therapies in the USA. 4 April 2019
Major US insurer Cigna has moved to cap insulin prices for customers, together with its new acquisition Express Scripts, a pharmacy benefits manager (PBM). 4 April 2019
French privately-held biotech firm Enterome Bioscience has named Jan Fagerberg its new chief medical officer and Catherine Mathis its chief development officer. 3 April 2019
Daniel Welch, the man who previously headed up several biotechs that were sold to pharma majors over the past several years, has joined privately-held US biopharma company InCarda Therapeutics as executive chairman. 3 April 2019
The Pan American Health Organization (PAHO) and non-profit PATH have published a report detailing the opportunities to improve vaccine programs through effective data use. 3 April 2019